1. Biochemistry and Chemical Biology
Download icon

Skd3 (human CLPB) is a potent mitochondrial protein disaggregase that is inactivated by 3-methylglutaconic aciduria-linked mutations

  1. Ryan R Cupo
  2. James Shorter  Is a corresponding author
  1. University of Pennsylvania, United States
Research Article
  • Cited 0
  • Views 551
  • Annotations
Cite this article as: eLife 2020;9:e55279 doi: 10.7554/eLife.55279

Abstract

Cells have evolved specialized protein disaggregases to reverse toxic protein aggregation and restore protein functionality. In nonmetazoan eukaryotes, the AAA+ disaggregase Hsp78 resolubilizes and reactivates proteins in mitochondria. Curiously, metazoa lack Hsp78. Hence, whether metazoan mitochondria reactivate aggregated proteins is unknown. Here, we establish that a mitochondrial AAA+ protein, Skd3 (human CLPB), couples ATP hydrolysis to protein disaggregation and reactivation. The Skd3 ankyrin-repeat domain combines with conserved AAA+ elements to enable stand-alone disaggregase activity. A mitochondrial inner-membrane protease, PARL, removes an autoinhibitory peptide from Skd3 to greatly enhance disaggregase activity. Indeed, PARL-activated Skd3 dissolves α-synuclein fibrils connected to Parkinson's disease. Human cells lacking Skd3 exhibit reduced solubility of various mitochondrial proteins, including anti-apoptotic Hax1. Importantly, Skd3 variants linked to 3-methylglutaconic aciduria, a severe mitochondrial disorder, display diminished disaggregase activity (but not always reduced ATPase activity), which predicts disease severity. Thus, Skd3 is a potent protein disaggregase critical for human health.

Article and author information

Author details

  1. Ryan R Cupo

    Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. James Shorter

    Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, United States
    For correspondence
    jshorter@pennmedicine.upenn.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5269-8533

Funding

National Institutes of Health (R01GM099836)

  • James Shorter

National Institutes of Health (F31AG060672)

  • Ryan R Cupo

National Institutes of Health (T32GM008275)

  • Ryan R Cupo

Blavatnik Family Foundation (Blavatnik Family Foundation Fellowship)

  • Ryan R Cupo

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. James M Berger, Johns Hopkins University School of Medicine, United States

Publication history

  1. Received: January 19, 2020
  2. Accepted: June 22, 2020
  3. Accepted Manuscript published: June 23, 2020 (version 1)

Copyright

© 2020, Cupo & Shorter

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 551
    Page views
  • 117
    Downloads
  • 0
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)

Further reading

    1. Biochemistry and Chemical Biology
    2. Plant Biology
    Pengxiang Fan et al.
    Research Article
    1. Biochemistry and Chemical Biology
    2. Cell Biology
    Senem Aykul et al.
    Research Article Updated